{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:32:21Z","timestamp":1792668741084,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous category of disease entities occurring in the context of iatrogenic immune suppression. Epstein-Barr virus (EBV)\u2013driven B-cell lymphoproliferation represents the prototype of quintessential PTLD, which includes a range of histologies named nondestructive, polymorphic, and monomorphic EBV+ diffuse large B-cell lymphoma (DLBCL) PTLD. While EBV is associated with the majority of PTLD cases, other drivers of lymphoid neoplasia and lymphoma transformation can occur\u2014with or without EBV as a codriver\u2014thus underlining its vast heterogeneity. In this review, we discuss the evolution in contemporary PTLD nomenclature and its emphasis on more precise subcategorization, with a focus on solid organ transplants in children, adolescents, and young adults. We highlight the fact that patients with quintessential EBV-associated PTLD\u2014including those with monomorphic DLBCL\u2014can be cured with low-intensity therapeutic approaches such as reduction in immune suppression, surgical resection, rituximab monotherapy, or rituximab plus low-dose chemotherapy. There is, though, a subset of patients (approximately 30%-40%) with quintessential PTLD that remains refractory to lower-intensity approaches, for whom intensive, lymphoma-specific chemotherapy regimens are required. Other forms of monomorphic PTLD, which are as diverse as the spectrum of defined lymphoma entities that also occur in immunocompetent patients, are rarely cured with lower-intensity therapies and appear to be better categorized as posttransplant lymphomas. These distinct scenarios represent the variations in lymphoid pathology that make up a conceptual framework for PTLD consisting of lymphoid hyperplasia, neoplasia, and malignancy. This framework serves as the basis to inform risk stratification and determination of evidence-based treatment strategies.<\/jats:p>","DOI":"10.1182\/hematology.2024000583","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:06:58Z","timestamp":1733497618000},"page":"728-735","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["EBV and post-transplant lymphoproliferative disorder: a complex relationship"],"prefix":"10.1182","volume":"2024","author":[{"given":"Nader Kim","family":"El-Mallawany","sequence":"first","affiliation":[{"name":"1 Department of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, TX"},{"name":"2 Texas Children's Cancer and Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[{"name":"1 Department of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, TX"},{"name":"2 Texas Children's Cancer and Hematology Center, Houston, TX"},{"name":"3 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"1","key":"2024121115405991700_hem2024000583C1","doi-asserted-by":"crossref","first-page":"101446","DOI":"10.1016\/j.beha.2023.101446","article-title":"Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults","volume":"36","author":"Rubinstein","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2S1","key":"2024121115405991700_hem2024000583C2","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","article-title":"OPTN\/SRTR 2022 Annual Data Report: kidney","volume":"24","author":"Lentine","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2024121115405991700_hem2024000583C3","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajt.2024.01.014","article-title":"OPTN\/SRTR 2022 Annual Data Report: liver","volume":"24","author":"Kwong","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2024121115405991700_hem2024000583C4","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.ajt.2024.01.016","article-title":"OPTN\/SRTR 2022 Annual Data Report: heart","volume":"24","author":"Colvin","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2024121115405991700_hem2024000583C5","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.ajt.2024.01.017","article-title":"OPTN\/SRTR 2022 Annual Data Report: lung","volume":"24","author":"Valapour","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2024121115405991700_hem2024000583C6","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/j.ajt.2024.01.015","article-title":"OPTN\/SRTR 2022 Annual Data Report: intestine","volume":"24","author":"Horslen","year":"2024","journal-title":"Am J Transplant"},{"issue":"5","key":"2024121115405991700_hem2024000583C7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.2022019543","article-title":"Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders","volume":"142","author":"Salmer\u00f3n-Villalobos","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2024121115405991700_hem2024000583C8","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"issue":"20","key":"2024121115405991700_hem2024000583C9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024121115405991700_hem2024000583C10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00043426-200101000-00005","article-title":"Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior","volume":"23","author":"Hayashi","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2024121115405991700_hem2024000583C11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Ferreiro","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"2024121115405991700_hem2024000583C12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.5858\/arpa.2023-0323-RA","article-title":"Clinicopathologic spectrum of pediatric posttransplant lymphoproliferative diseases following solid organ transplant","volume":"148","author":"Cheng","year":"2024","journal-title":"Arch Pathol Lab Med"},{"issue":"18","key":"2024121115405991700_hem2024000583C13","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency- associated lymphoproliferative disorders: time for reappraisal?","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2024121115405991700_hem2024000583C14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2024121115405991700_hem2024000583C15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024121115405991700_hem2024000583C16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/j.semdp.2018.02.001","article-title":"Reexamining post-transplant lymphoproliferative disorders: newly recognized and enigmatic types","volume":"35","author":"Aguilera","year":"2018","journal-title":"Semin Diagn Pathol"},{"issue":"10","key":"2024121115405991700_hem2024000583C17","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1111\/ajt.15358","article-title":"Posttransplant lymphoproliferative disorder in pediatric patients: survival rates according to primary sites of occurrence and a proposed clinical categorization","volume":"19","author":"L'Huillier","year":"2019","journal-title":"Am J Transplant"},{"issue":"4","key":"2024121115405991700_hem2024000583C18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1309\/AJCPQYYE04AVGVYI","article-title":"Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation","volume":"138","author":"Nelson","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2024121115405991700_hem2024000583C19","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"2024121115405991700_hem2024000583C20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood.2023020768","article-title":"Evolving beyond morphology in pediatric PTLD","volume":"142","author":"El-Mallawany","year":"2023","journal-title":"Blood"},{"issue":"27","key":"2024121115405991700_hem2024000583C21","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1200\/JCO.2005.08.074","article-title":"Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation","volume":"23","author":"Gross","year":"2005","journal-title":"J Clin Oncol"},{"issue":"31","key":"2024121115405991700_hem2024000583C22","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"2024121115405991700_hem2024000583C23","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1182\/blood.V124.21.4468.4468","article-title":"Response-adapted sequential immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective Ped-PTLD 2005 trial","volume":"124","author":"Maecker-Kolhoff","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2024121115405991700_hem2024000583C24","doi-asserted-by":"crossref","first-page":"e31053","DOI":"10.1002\/pbc.31053","article-title":"Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: a multicentre international experience","volume":"71","author":"Guerra-Garc\u00eda","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2024121115405991700_hem2024000583C25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","article-title":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study","volume":"8","author":"Wistinghausen","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2024121115405991700_hem2024000583C26","doi-asserted-by":"crossref","first-page":"e14292","DOI":"10.1111\/petr.14292","article-title":"Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients","volume":"26","author":"Quintero Bernabeu","year":"2022","journal-title":"Pediatr Transplant"},{"issue":"6","key":"2024121115405991700_hem2024000583C27","doi-asserted-by":"crossref","first-page":"e14042","DOI":"10.1111\/petr.14042","article-title":"Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients","volume":"25","author":"Zierhut","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"3","key":"2024121115405991700_hem2024000583C28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.18498","article-title":"Burkitt lymphoma after solid- organ transplant: treatment and outcomes in the paediatric PTLD collaborative","volume":"200","author":"Afify","year":"2023","journal-title":"Br J Haematol"},{"issue":"23","key":"2024121115405991700_hem2024000583C29","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2024121115405991700_hem2024000583C30","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/cncr.34600","article-title":"Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders","volume":"129","author":"Afify","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"2024121115405991700_hem2024000583C31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10428194.2016.1205742","article-title":"Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules","volume":"58","author":"Kampers","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024121115405991700_hem2024000583C32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.24346","article-title":"Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival","volume":"91","author":"Rosenberg","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121115405991700_hem2024000583C33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/TP.0b013e3182762e07","article-title":"Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases","volume":"95","author":"Tiede","year":"2013","journal-title":"Transplantation"},{"issue":"2","key":"2024121115405991700_hem2024000583C34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/pbc.21072","article-title":"Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation","volume":"50","author":"Yang","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2024121115405991700_hem2024000583C35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2012-06-438549","article-title":"Early onset, EBV(-) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis","volume":"121","author":"Perry","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2024121115405991700_hem2024000583C36","doi-asserted-by":"crossref","first-page":"E137","DOI":"10.1002\/pbc.24632","article-title":"Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients","volume":"60","author":"Plant","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024121115405991700_hem2024000583C37","doi-asserted-by":"crossref","first-page":"e14743","DOI":"10.1111\/petr.14743","article-title":"Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: a case series from the Pediatric Nephrology Research Consortium","volume":"28","author":"Ashoor","year":"2024","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2024121115405991700_hem2024000583C38","doi-asserted-by":"crossref","first-page":"e14350","DOI":"10.1111\/petr.14350","article-title":"The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: II-consensus guidelines for prevention","volume":"28","author":"Green","year":"2024","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2024121115405991700_hem2024000583C39","doi-asserted-by":"crossref","first-page":"e14471","DOI":"10.1111\/petr.14471","article-title":"The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: III - consensus guidelines for Epstein-Barr virus load and other biomarker monitoring","volume":"28","author":"Preiksaitis","year":"2024","journal-title":"Pediatr Transplant"},{"issue":"19","key":"2024121115405991700_hem2024000583C40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/728\/2346848\/728el-mallawany.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/728\/2346848\/728el-mallawany.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:11:00Z","timestamp":1733947860000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/728\/526221\/EBV-and-post-transplant-lymphoproliferative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000583","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}